Skip to main navigation Skip to search Skip to main content

Na+/H+-exchange inhibition by cariporide is compensated via Na+,HCO3−-cotransport and has no net growth consequences for ErbB2-driven breast carcinomas

  • Pernille Aaen
  • , Kristoffer B. Kristensen
  • , Arththy Antony
  • , Steen H. Hansen
  • , Claus Cornett
  • , Stine F. Pedersen
  • , Ebbe Boedtkjer*
  • *Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

54 Downloads (Pure)

Abstract

Defense against intracellular acidification of breast cancer tissue depends on net acid extrusion via Na+,HCO3−-cotransporter NBCn1/Slc4a7 and Na+/H+-exchanger NHE1/Slc9a1. NBCn1 is increasingly recognized as breast cancer susceptibility protein and promising therapeutic target, whereas evidence for targeting NHE1 is discordant. Currently, selective small molecule inhibitors exist against NHE1 but not NBCn1. Cellular assays—with some discrepancies—link NHE1 activity to proliferation, migration, and invasion; and disrupted NHE1 expression can reduce triple-negative breast cancer growth. Studies on human breast cancer tissue associate high NHE1 expression with reduced metastasis and—in some molecular subtypes—improved patient survival. Here, we evaluate Na+/H+-exchange and therapeutic potential of the NHE1 inhibitor cariporide/HOE-642 in murine ErbB2-driven breast cancer. Ex vivo, cariporide inhibits net acid extrusion in breast cancer tissue (IC50 = 0.18 μM) and causes small decreases in steady-state intracellular pH (pHi). In vivo, we deliver cariporide orally, by osmotic minipumps, and by intra- and peritumoral injections to address the low oral bioavailability and fast metabolism. Prolonged cariporide administration in vivo upregulates NBCn1 expression, shifts pHi regulation towards CO2/HCO3−-dependent mechanisms, and shows no net effect on the growth rate of ErbB2-driven primary breast carcinomas. Cariporide also does not influence proliferation markers in breast cancer tissue. Oral, but not parenteral, cariporide elevates serum glucose by ∼1.5 mM. In conclusion, acute administration of cariporide ex vivo powerfully inhibits net acid extrusion from breast cancer tissue but lowers steady-state pHi minimally. Prolonged cariporide administration in vivo is compensated via NBCn1 and we observe no discernible effect on growth of ErbB2-driven breast carcinomas.

Original languageEnglish
Article number167450
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1870
Issue number7
Number of pages13
ISSN0925-4439
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s)

Funding

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ebbe Boedtkjer reports equipment, drugs, or supplies was provided by Sanofi-Aventis Deutschland GmbH. Kristoffer B. Kristensen reports financial support was provided by Danish Cancer Society. Ebbe Boedtkjer reports financial support was provided by Danish Cancer Society. Ebbe Boedtkjer reports financial support was provided by Novo Nordisk Foundation. Stine F. Pedersen reports a relationship with Solid Therapeutics ApS that includes: board membership and equity or stocks. Ebbe Boedtkjer has patent #EP-3271402 issued to Aarhus University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors would like to thank Jane R\u00F8nn and Viola Larsen for expert technical assistance. This study was financially supported by the Danish Cancer Society (R168-A10843 to K.B.K. and R72-A4273 to E.B.), and the Novo Nordisk Foundation (NNF18OC0053037 to E.B.). Cariporide was a kind gift from Sanofi-Aventis Deutschland GmbH. Funding sources and sponsors played no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors would like to thank Jane R\u00F8nn and Viola Larsen for expert technical assistance. This study was financially supported by the Danish Cancer Society ( R168-A10843 to K.B.K. and R72-A4273 to E.B.), and the Novo Nordisk Foundation ( NNF18OC0053037 to E.B.). Cariporide was a kind gift from Sanofi-Aventis Deutschland GmbH. Funding sources and sponsors played no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Keywords

  • Breast cancer
  • Cariporide
  • ErbB2
  • HER2
  • Intracellular pH
  • NBCn1
  • NHE1
  • Slc4a7
  • Slc9a1

Cite this